Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 2/20 | 0.35 |
| ▸ | FLT1 | P17948 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.34 |
| ▸ | STK17B | O94768 | 1/20 | 0.31 |
| ▸ | MAP3K8 | P41279 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27768365 | 0.84 | CHEK1 (0.35) | MCHR1FLT1KDRCHEK1STK17B | |
| SCHEMBL29012242 | 0.82 | FLT1 (0.42) | FLT1KDRCHEK1LMNA | |
| SCHEMBL12922013 | 0.81 | CHEK1 (0.39) | MCHR1CHEK1STK17BMAP3K8ACHE | |
| SCHEMBL8827320 | 0.80 | CHEK1 (0.49) | MCHR1CHEK1STK17BMAP3K8ACHE | |
| SCHEMBL12922014 | 0.78 | CHEK1 (0.40) | MCHR1CHEK1STK17BMAP3K8ACHE | |
| SCHEMBL12922040 | 0.76 | MAPT (0.41) | CHEK1STK17BACHE | |
| SCHEMBL28776699 | 0.76 | CHEK1 (0.34) | CHEK1STK17BMAP3K8KDM4ELMNA | |
| SCHEMBL28781348 | 0.75 | MCHR1 (0.39) | MCHR1CHEK1 | |
| SCHEMBL26983380 | 0.74 | MCHR1 (0.35) | MCHR1CHEK1 | |
| SCHEMBL27768315 | 0.73 | CHEK1 (0.41) | MCHR1CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115038439-A | Combination cancer therapy with CHK inhibitors | 上海华禹生物科技有限公司 | 2022-09-09 | — | — | CN | claimed |
| CN-115038440-A | Combination cancer therapy with CHK inhibitors | 上海华禹生物科技有限公司 | 2022-09-09 | — | — | CN | claimed |
| CN-101481380-A | Thiofuran pyridazine compound, preparation thereof, pharmaceutical composition and uses thereof | ZHEJIANG MEDICINE CO LTD (CN) | 2009-07-15 | — | — | CN | claimed |
| CN-115038439-A | Combination cancer therapy with CHK inhibitors | 上海华禹生物科技有限公司 | 2022-09-09 | — | — | CN | disclosed |
| CN-115038440-A | Combination cancer therapy with CHK inhibitors | 上海华禹生物科技有限公司 | 2022-09-09 | — | — | CN | disclosed |
| CN-101481380-A | Thiofuran pyridazine compound, preparation thereof, pharmaceutical composition and uses thereof | ZHEJIANG MEDICINE CO LTD (CN) | 2009-07-15 | — | — | CN | disclosed |